1.	LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.13, 2007-004803-36, NCT00805194
2.	Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.14, 2008-002072-10, NCT00806819
3.	LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.15, AGO-OVAR12, 2008-006831-10, NCT01015118
4.	A Multi-Centre 3-Arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-Resistant Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1239.3, NCT00706628
5.	A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.9, EUDRACT2005-002427-14, CRUK-1199.9, EU-20631, CRUK-BIBF1120, BOEHRINGER-CRUK-1199.9, NCT00710762
6.	BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.51, 2008-005364-14, NCT00904839
7.	Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.26, 2009-009516-44, NCT01024920
8.	BIBF 1120 in Recurrent Glioblastoma Multiforme Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BIBF1120 GBM, NCT01251484
9.	BIBF 1120 for Recurrent High-Grade Gliomas Phase: Phase II Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11-055, BIBF 1199.94, NCT01380782
10.	A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120 Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.16, NCT00715403
11.	Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1239.1, NCT00730821
12.	BIBF 1120 + Docetaxel(Japan), Phase I Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.29, NCT00876460
13.	BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.28, NCT00979576
14.	Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.7, 2008-008304-41, NCT01022853
15.	Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1199.117, NCT01329549